RBC Capital analyst Brian Abrahams maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of $160.00. The company's shares closed last Wednesday at $95.18, close to its 52-week high of $101.24. According to TipRanks.com, Abrahams is a 2-star analyst with an average return of -0.1% and a 45.8% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Karyopharm Therapeutics, and Vertex Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $129.87 average price target, representing a 37.7% upside.
https://www.tipranks.com/news/blurbs/rbc-capital-believes-sarepta-therapeutics-srpt-still-has-room-to-grow?utm_source=advfn.com&utm_medium=referral
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Sarepta Therapeutics Charts.
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Sarepta Therapeutics Charts.